PRIMARY OBJECTIVE: To investigate effectiveness of donepezil hydrochloride (Aricept®) in treating persistent memory deficits in persons with traumatic brain injury.
RESEARCH DESIGN: Single subject ABAC design was used so that each participant could serve as their own control.
METHODS AND PROCEDURES: Seven TBI survivors with persistent memory dysfunction, at least 1 ½ years post-injury, underwent two, six-month trials of Aricept®. The following tests were used to assess memory and cognition: Brief Visual Memory Test-Revised (BVMT-R), Hopkins Verbal Learning Test, Digit Span and Letter Number Sequence subtest of the Wechsler Adult Intelligence Scale-III, Controlled Oral Word Association Test, and Memory Functioning Questionnaire.
EXPERIMENTAL INTERVENTION: During first treatment phase, participants received 5mg/day of Aricept® for one month, increasing to 10mg/day of Aricept® for an additional five months. During second treatment phase, participants received 5mg/day of Aricept® for the entire six months.
MAIN OUTCOMES AND RESULTS: A repeated measures analysis of variance indicated significant improvement on immediate and delayed memory portions of the BVMT-R when taking 10mg/day of Aricept®.
CONCLUSIONS: Findings contribute to the growing body of research into the use of Aricept® in treating memory deficits in TBI survivors and support need for further research.
Registry Project Number: 52
Lead Investigator: Cilo, M
Lead Center for Project: Craig Hospital
Collaborating Investigators: Morey, C, Berry, J, Cusick, C
Keywords: memory, medication, traumatic brain injury
Date of Completion: 03/01/2001
Status of Project: Latest Information Shown
View publications linked to this project
email the author of this project